Table 5 EGFRvIII mutation is associated with disease control

EGFRvIII absent by ΔΔCt

12 (67%)

6 (33%)

P = 0.0099

EGFRvIII present by ΔΔCt

5 (25%)

15 (75%)

(Chi-square)

EGFRvIII mean fold change

10.62

63.76

P = 0.04

EGFRvIII median fold change

3.16

11.11

(Wilcoxon)

Erlotinib treated patients

   EGFRvIII absent by ΔΔCt

6 (55%)

5 (45%)

P = 0.21

   EGFRvIII present by ΔΔCt

3 (33%)

10 (77%)

(Fisher's)

Non-erlotinib treated patients

   EGFRvIII absent by ΔΔCt

6 (86%)

1 (14%)

P = 0.21

   EGFRvIII present by ΔΔCt

2 (29%)

5 (71%)

(Fisher's)